Prospective Validation of a Novel Strategy for Assessing Risk of Significant Hyperbilirubinemia

• Tipo: Artigo em Revista Científica Internacional
• Data: 2011

Autores

Goncalves, A (Autor) Outra; Costa, S (Autor) Outra; Lopes, A (Autor) Outra; Rocha, G (Autor) Outra; Guedes, MB (Autor) Outra; Centeno, MJ (Autor) Outra; Silva, J (Autor) Outra; Silva, MG (Autor) Outra; Severo M (Autor) FMUP; Guimarães H (Autor) FMUP

Revista

Título: Pediatrics

Vol. 127

Páginas: E126-E131

ISSN: 0031-4005

Editora: American Academy of Pediatrics

Indexação

ISI Web of Knowledge - 7 Citações

Scopus - 6 Citações

Pubmed / Medline

Classificação Científica

FOS: Ciências médicas e da saúde > Outras ciências médicas

CORDIS: Ciências da Saúde > Ciências Médicas > Medicina > Pediatria

Outras Informações

ID Authenticus: P-002-ZA9

DOI: 10.1542/peds.2009-2771

Abstract (EN): OBJECTIVE: Our aim was to validate a strategy for assessing the risk of significant hyperbilirubinemia in newborns with gestational ages of >= 35 weeks by combining predischarge bilirubin percentile data with gestational age data, for a European, predominantly white population. METHODS: We conducted a prospective cohort study with 463 newborns with gestational ages of >= 35 weeks who were admitted to the well-infant nursery. Total bilirubin levels were measured daily until discharge and once after discharge, between the third and eighth days of life, by using a Bilicheck device (Respironics, Murrysville, PA). The values obtained (<52 hours) were plotted on an hour-specific bilirubin nomogram to determine the infant's bilirubin percentile, expressed as a risk zone. Patients were assigned to 1 of 3 risk groups (very low, low, or high) on the basis of a combination of risk zone and gestational age data and were monitored prospectively for the development of significant hyperbilirubinemia. The 95% confidence interval (CI) for the prevalence of significant hyperbilirubinemia was estimated with the binomial distribution method. RESULTS: Forty-four infants (11%) developed significant neonatal hyperbilirubinemia. The risks of developing significant hyperbilirubinemia were 1.3% (95% CI: 0.2%-3.7%) for the very low risk group (n = 230 [58.1%]), 3.4% (95% CI: 0.7%-9.8%) for the low risk group (n = 86 [21.7%]), and 47.50% (95% CI: 36.2%-59.0%) for the high risk group (n = 80 [20.20%]). CONCLUSIONS: The proposed strategy, based on predischarge bilirubin level and gestational age data, was a valid method for significant hyperbilirubinemia risk assessment in our population. Pediatrics 2011;127:e126-e131

Idioma: Inglês

Tipo (Avaliação Docente): Científica

Nº de páginas: 6